Results 101 to 110 of about 187,113 (345)

Characterization of an Injectable Poly(vinyl alcohol)‐gelatin Hydrogel for Growth Factor Delivery in an Orthopedic Application

Advanced Healthcare Materials, EarlyView.
This work introduces photo‐crosslinkable tyraminated poly(vinyl alcohol)‐gelatin (PVA‐GT) hydrogels as tunable injectable platforms for tissue engineering and growth factor delivery applications. This schematic illustrates the two developed hydrogel formulations and the experimental workflow used to evaluate their physico‐chemical properties in vitro ...
Alessia Longoni, Gretel S. Major, Sam Arnold, Samuel Tomkins, Eugenia Spessot, Scott Loeffler, Kieran Lau, Richard Tan, Jessica Harte, Roslyn Kemp, Tess Reynolds, Jelena Rnjak‐Kovacina, Gary J. Hooper, Tim B. F. Woodfield, David C. Kieser, Khoon S. Lim   +15 more
wiley   +1 more source

Liver transplantation and non-alcoholic fatty liver disease

World Journal of Gastroenterology, 2014
Non-alcoholic fatty liver disease (NAFLD) is an important health problem worldwide. NAFLD encompasses a histological spectrum ranging from bland liver steatosis to severe steatohepatitis (nonalcoholic steatohepatitis, NASH) with the potential of progressing to cirrhosis and its associated morbidity and mortality.
Petros, Zezos, Eberhard L, Renner
openaire   +2 more sources

Microneedle Technology in Psoriasis Management: Mechanistic Insights, Technological Innovation, Clinical Progress, and Challenges

Advanced Healthcare Materials, EarlyView.
This review explores the evolving role of microneedle systems in psoriasis management, highlighting their potential for enhanced drug delivery, diagnosis, and disease monitoring. It also discusses unmet clinical needs for psoriasis management and technical challenges, while outlining strategic directions to advance microneedle integration into routine ...
Fatma Moawad, Yasmine Ruel, Roxane Pouliot, Davide Brambilla   +3 more
wiley   +1 more source

Recent advances in understanding and managing non-alcoholic fatty liver disease [version 1; referees: 2 approved]

F1000Research, 2018
Non-alcoholic fatty liver disease is a leading cause of chronic liver disease that can lead to cirrhosis, hepatocellular cancer, and end-stage liver disease, and it is linked to elevated cardiovascular- and cancer-related morbidity and mortality. Insulin
Somaya Albhaisi, Arun Sanyal
doaj   +1 more source

Paediatric non-alcoholic fatty liver disease: impact on patients and mothers' quality of life [PDF]

, 2013
Background: Non-alcoholic fatty liver disease (NAFLD) is one of the causes of fatty liver in adults and is currently the primary form of chronic liver disease in children and adolescents. However, the psychological outcome (i.e.
Armando, M, Bedogni, G, De Peppo, L, Della Corte, C, Fatta, L, Fatta, LAURA MARIA, Lofino, G, Mazzone, L, Nobili, V., Postorino, V, Vassena, L, Vicari, S   +11 more
core   +2 more sources

Biofilm‐Antagonist Ginger‐Based 3D‐Printable Photoresins for Complex Implant Designs Exhibiting Advanced Multifunctional Biomedical Applications

Advanced Materials, EarlyView.
This work offers unique Ginger‐based 3D‐printable resins that can print customizable high‐resolution complex designs. The customizable printing backbone of Zingerol prints also mimics various human bones' strength. Acquisition of in‐vivo biocompatibility in rat model with no severe inflammatory response, along with in‐vitro antioxidant and ex‐vivo anti‐
Simran Jindal, Majd Bisharat, Bassma Khamaisi, Krishanu Ghosal, Eid Nassar‐Marjiya, Qi Wu, Shadi Daoud, Idan Redenski, Samer Srouji, Shady Farah   +9 more
wiley   +1 more source

Evaluation of polygenic determinants of non-alcoholic fatty liver disease (NAFLD) by a candidate genes resequencing strategy [PDF]

, 2018
NAFLD is a polygenic condition but the individual and cumulative contribution of identified genes remains to be established. To get additional insight into the genetic architecture of NAFLD, GWAS-identified GCKR, PPP1R3B, NCAN, LYPLAL1 and TM6SF2 genes ...
Angelico F, Angeloni A, Arca M, Bailetti D, Baratta F, Belardinilli F, Ceci F, D'Erasmo L, De Masi B, Del Ben M, Di Costanzo A, Giannini G, Girelli G, Montali A, Pastori D, Polimeni L, Sponziello M   +16 more
core   +1 more source

Bacteria‐Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy

Advanced Materials, EarlyView.
Bacteria‐responsive nanocarriers are designed to release antimicrobials only in the presence of infection‐specific cues. This selective activation ensures drug release precisely at the site of infection, avoiding premature or indiscriminate release, and enhancing efficacy.
Guillermo Landa, Gracia Mendoza, Silvia Irusta, Manuel Arruebo   +3 more
wiley   +1 more source

Additive effect of non-alcoholic fatty liver disease on metabolic syndrome-related endothelial dysfunction in hypertensive patients [PDF]

, 2016
Metabolic syndrome (MS) is characterized by an increased risk of incident diabetes and cardiovascular (CV) events, identifying insulin resistance (IR) and endothelial dysfunction as key elements.
Caroleo, B, Cimellaro, A, Maio, R, Perticone, F, Perticone, M, Sciacqua, A, Sesti, G   +6 more
core   +3 more sources

Non-Alcoholic Fatty Liver Disease

Proceedings of Singapore Healthcare, 2010
Non-alcoholic fatty liver disease (NAFLD) comprises a disease spectrum ranging from benign hepatic steatosis to non-alcoholic steatohepatitis with inflammation (NASH) and liver cirrhosis.
Hui-Hui Tan MRCP(UK), FAMS, Jason Pik-Eu Chang MMed (Int Med), MRCP(UK)   +1 more
doaj   +1 more source